ARR

(redirected from Annualized Relapse Rate)
AcronymDefinition
ARRAll Rights Reserved
ARRA Realm Reborn (gaming)
ARRArrangement
ARRArrival
ARRArrive
ARRArrange
ARRAgencja Rynku Rolnego (Polish: Agricultural Market Agency)
ARRA.R. Rahman (Indian composer)
ARRAlmost Ready to Run (R/C kits)
ARRAgencja Rozwoju Regionalnego (Polish: Regional Development Agency)
ARRAlaska Railroad
ARRAbsolute Risk Reduction
ARRAnnualized Relapse Rate (patient statistic)
ARRAdjusted Rate of Return (finance)
ARRAutomatic Retransmission Request
ARRAsynchronous Reply Required
ARRApplication Recovery and Restart
ARRAddress Region Register
ARRAnnual Run Rate (finance)
ARRAccounting Rate of Return
ARRAverage Room Rate (hotel Industry)
ARRAnnual Revenue Requirement
ARRAnnualized Return Rate (finance)
ARRAdministrative Rule Review (various locations)
ARRAndøya Rocket Range
ARRAutomatic Repeat Request
ARRAutoritatea Rutiera Romana (Romanian Road Authority)
ARRAcademy of Radiology Research (Washington, DC)
ARRAfforestation, Reforestation, Revegetation
ARRAnalyse des Risques Résiduels (French: Residual Risk Analysis)
ARRAgeing Research Reviews
ARRArtist's Resale Right (EC intellectual property right)
ARRAudit and Risk Review
ARRAnnual Recurring Revenue
ARRAssessment, Recording and Reporting (UK schools)
ARRArizona Road Racers
ARRAnnual Resident Review
ARRAssociation for Radiation Research (UK)
ARRAnnual Replacement Rate
ARRAverage Room Rent
ARRAlbany River Rats (hockey team)
ARRAxel Roxas Reno (dolls)
ARRAttributes for Representing Relationships
ARRAmerican River Recreation (Lotus, CA)
ARRAdmissions, Recruitment and Registrar's Office (McGill University office)
ARRAutomatic Re-Routing
ARRAlert Readiness Rate
ARRAirborne Radio Receiver
ARRAttack Relevance Rating (Cisco)
ARRAllowance Requirements Registers
ARRAdult Employment Retention Rate
ARRAnno Regni Regis/Reginae (in the year of the king/queen's reign)
ARRAnti-Repeat Relay
ARRAvailability Readiness Review (US Navy)
ARRAirborne Reference Radar
ARRAssemble Test and Launch Operations (ATLO) Readiness Review (NASA)
ARRAverage Reward Rate
ARRAcceptable Risk Range
ARRArmy Readiness Regions
ARRArmour Research Reactor
ARRAsteroid Radar Research
ARRAntenna Rotation Rate
ARRAbingdon Rough Riders (San Francisco, CA)
ARRAnnual Recurring Requirement
ARRAcquisition Requirements Record
ARRArmy Retail Requirements
ARRAnnual Results Report (various organizations)
ARRAssociation for Regulatory Reform
ARRArkansas Rides (automotive enthusiast forum)
ARRActive Rebuilders and Restorers
References in periodicals archive ?
Both studies met the primary endpoints where ofatumumab showed a highly significant and clinically meaningful reduction in the number of confirmed relapses, evaluated as the annualized relapse rate (ARR)[1].
Both studies met the primary endpoints where ofatumumab showed a highly significant and clinically meaningful reduction in the number of confirmed relapses, evaluated as the annualized relapse rate. Key secondary endpoints of delaying time to confirmed disability progression were also met.
Compared with nonoverweight patients, obese patients had statistically significantly more relapses on first-line treatment with interferon beta and glatiramer acetate (annualized relapse rate, 1.29 versus 0.72) and a higher rate of second-line treatment (56.8 versus 38.7 percent).
New results in 696 MS patients on diroximel fumarate showed a significant reduction in the annualized relapse rate (ARR) by 79 percent over one year when compared to baseline, and by 82 percent in newly diagnosed patients.
Ocrelizumab was shown to be effective and safe in two phase III trials conducted in RRMS patients with a significant reduction in annualized relapse rate (ARR), which confirmed disability progression and new MRI lesions [5].
In a review of 139 Japanese women with NMOSD, the study authors noted an increased annualized relapse rate (ARR) during the first three months postpartum compared to pre-pregnancy; however, the ARR was not reduced during pregnancy [8].
It is the first and only oral short-course treatment to provide efficacy across key measures, including disability progression, annualized relapse rate and magnetic resonance imaging (MRI) activity.
Celgene's Phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR), compared to weekly interferon (IFN) [beta]-1a (Avonex).
The mean age of these patients was 43 years (SD: 12); the mean duration of the disease 11.6 years (SD: 8.8); the mean expanded disability status scale is 4.1 (SD: 1.9); and the annualized relapse rate is 2.9 (SD: 1.7).
In those of African descent, the cumulative 0- to 5-year annualized relapse rate was 0.16.
Comparison of the various parameters between patients divided into two groups according to the continuation of the immunmodulatory treatment Group 1 Group 2 Annualized relapse rate .68 [+ or -] .82 .61 [+ or -] .46 BDI score 12.84 [+ or -] 9.55 13.24 [+ or -] 9.85 PASAT score .62 [+ or -] .22 .64 [+ or -] .27 EDSS score 2.52 [+ or -] 1.57 3.98 [+ or -] 2.30 Mean age (years) 39.99 [+ or -] 10.2 42.90 [+ or -] 10.69 Education period (years) 9.48 [+ or -] 4.05 9.19 [+ or -] 4.24 Disease duration (years) 10.24 [+ or -] 6.04 12.40 [+ or -] 6.20 p Annualized relapse rate .57 BDI score .88 PASAT score .2 EDSS score <.0001 * Mean age (years) .08 Education period (years) .65 Disease duration (years) .03 * Group 1: under treatment, Group 2: discontinued the treatment.